Провоспалительные цитокины при хронической сердечной недостаточности: состояние проблемы - Журнал Терапевтический архив №11 Инфекционные болезни 2021

Провоспалительные цитокины при хронической сердечной недостаточности: состояние проблемы

Коротаева А.А., Самойлова Е.В., Миндзаев Д.Р., Насонова С.Н., Жиров И.В., Терещенко С.Н. Провоспалительные цитокины при хронической сердечной недостаточности: состояние проблемы. Терапевтический архив. 2021;93(11):1389–1394. DOI: 10.26442/00403660.2021.11.201170

________________________________________________

Korotaeva AA, Samoilova EV, Mindzaev DR, Nasonova SN, Zhirov IV, Tereschenko SN. Pro-inflammatory cytokines in chronic cardiac failure: state of problem. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(11):1389–1394. DOI: 10.26442/00403660.2021.11.201170

Читать PDF

Аннотация

Системное воспаление характеризуется индукцией провоспалительных цитокинов, повышенный уровень которых в крови больных с хронической сердечной недостаточностью (ХСН) коррелирует с неблагоприятными клиническими исходами. Однако неясно, являются провоспалительные цитокины причиной или следствием прогрессирования заболевания. ХСН с сохраненной фракцией выброса и ХСН с низкой фракцией выброса имеют различные воспалительные особенности, что предполагает различную степень активации воспалительных путей. В обзоре рассматривается участие провоспалительных цитокинов в патофизиологических процессах развития ХСН, подчеркивается значение активации интерлейкина-6, влияние сопутствующих заболеваний на течение системного воспаления. В настоящее время продолжается активный поиск новых подходов к профилактике и лечению ХСН. В обзоре приводятся результаты клинических исследований таргетной антицитокиновой терапии, выявившие трудности в противодействии воспалению в хронических условиях сердечной недостаточности. Выявление специфических провоспалительных путей в патогенезе ХСН позволит управлять воспалительными каскадами и обеспечит перспективную терапевтическую стратегию.

Ключевые слова: сердечная недостаточность, воспаление, цитокины, интерлейкин-6, антицитокиновая терапия

________________________________________________

Systemic inflammation is characterized by the induction of pro-inflammatory cytokines, the increased level of which in the blood of patients with chronic heart failure (CHF) correlates with unfavorable clinical outcomes. However, it is unclear whether pro-inflammatory cytokines are the cause or the consequence of the disease progression. CHF with preserved ejection fraction and CHF with reduced ejection fraction demonstrate different inflammatory features, which suggests different degrees of pro-inflammatory pathway activation. The review deals with participation of pro-inflammatory cytokines in pathophysiological processes of CHF development, emphasizing the role of interleukin-6 activation and the effects of accompanying diseases on the course of systemic inflammation. The search for new approaches to prevention and therapy of CHF remains actual. The review presents the results of clinical trials of targeted anti-cytokine therapy which have revealed difficulties in controlling inflammation under the conditions of CHF. Identification of specific pro-inflammatory pathways in CHF pathogenesis will allow one to control inflammatory cascades, thus providing a prospective therapeutic strategy.

Keywords: heart failure, inflammation, cytokines, interleukin-6, anticytokine therapy

Полный текст

Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Терещенко С.Н., Галявич А.С., Ускач Т.М., и др. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):311‑74 [Tereshchenko SN, Galyavich AS, Uskach TM, et al. Clinical practice guidelines for Chronic heart failure 2020. Russian Journal of Cardiology. 2020;25(11):311-74 (in Russian)].
DOI:10.15829/1560-4071-2020-4083
2. Ponikowski P, Voors AA, Anker DS, et al. Рекомендации ESC по диагностике и лечению острой и хронической сердечной недостаточности 2016. Российский кардиологический журнал. 2017;1(141):7‑81 [Ponikowski P, Voors AA, Anker DS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Russian Journal of Cardiology. 2017;1(141):7-81 (in Russian)]. DOI:10.15829/1560-4071-2017-1-7-81
3. Li Z, Zhao H, Wang J. Metabolism and chronic inflammation: the links between chronic heart failure and comorbidities. Front Cardiovasc Med. 2021;8:650278. DOI:10.3389/fcvm.2021.650278
4. Mann DL. Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol. 2003;65:81-101.
DOI:10.1146/annurev.physiol.65.092101.142249
5. Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res. 2015;116:1254-68.
DOI:10.1161/CIRCRESAHA.116.302317
6. Hanna A, Frangogiannis NG. inflammatory cytokines and chemokines as therapeutic targets in heart failure. Cardiovasc Drugs Ther. 2020;34(6):849-63.
DOI:10.1007/s10557-020-07071-0
7. Kalogeropoulos A, Georgiopoulou V, Psaty BM, et al. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol. 2010;55(19):2129-37. DOI:10.1016/j.jacc.2009.12.045
8. van Wijk SS, van Empel V, Davarzani N, et al. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. Eur J Heart Fail. 2015;17:1006-14. DOI:10.1002/ejhf.414
9. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263-71.
DOI:10.1016/j.jacc.2013.02.092
10. Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018;39(1):26-35. DOI:10.1093/eurheartj/ehx564
11. Van Linthout S, Tschope СC. inflammation – cause or consequence of heart failure or both? Curr Heart Fail Rep. 2017;14(4):251-65. DOI:10.1007/s11897-017-0337-9
12. Gullestad L, Ueland T, Fjeld JG, et al. Effect ofthalidomide oncardiac remodelinginchronic heart failure: results of a double-blind, placebo-controlled study. Circulation. 2005;112(22):3408-14.
DOI:10.1161/CIRCULATIONAHA.105.564971
13. Skudicky D, Bergemann A, Sliwa K, et al. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study. Circulation. 2001;103(8):1083-8. DOI:10.1161/01.cir.103.8.1083
14. Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 2001;103(2):220-5. DOI:10.1161/01.cir.103.2.220
15. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107(25):3133-40. DOI:10.1161/01.CIR.0000077913.60364.D2
16. Mann DL, McMurray J, Packer M, et al. Targeted аnticytokine therapy in patients with chronic yeart failure. Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109(13):1594-602. DOI:10.1161/01.CIR.0000124490.27666.B2
17. Torre-Amione G, Anker SD, Bourge RC, et al. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet. 2008;371(9608):228-36. DOI:10.1016/S0140-6736(08)60134-8
18. Ridker PM, Everett BM, Thuren T, et al.; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-31. DOI:10.1056/NEJMoa1707914
19. Van Tassell BW, Trankle CR, Canada JM, et al. IL-1 blockade in patients with heart failure with preserved ejection fraction. Circ Heart Fail. 2018;11(8):e005036.
DOI:10.1161/CIRCHEARTFAILURE.118.005036
20. Abbate A, Trankle CR, Buckley LF, et al. Interleukin-1 Blockade Inhibits the Acute Inflammatory response in patients with st-segment-elevation myocardial infarction. Am J Cardiol. 2020;9(5):e014941. DOI:10.1161/JAHA.119.014941
21. Morton AC, Rothman AM, Greenwood JP, et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J. 2015;36:377-84. DOI:10.1093/eurheartj/ehu272
22. Yan AT, Yan RT, Cushman M, et al. Relationship of interleukin-6 with regional and global left-ventricular function in asymptomatic individuals without clinical cardiovascular disease: insights from the Multi-Ethnic Study of Atherosclerosis. Eur Heart J. 2010;31(7):875‑82. DOI:10.1093/eurheartj/ehp454
23. Harhay MO, Tracy RP, Bagiella E, et al. Relationship of CRP, IL‑6, and fibrinogen with right ventricular structure and function: The MESA-Right Ventricle Study. Int J Cardiol. 2013;168(4):3818-24. DOI:10.1016/j.ijcard.2013.06.028
24. Fontes JA, Rose NR, Cihakova D. The varying faces of IL-6: from cardiac protection to cardiac failure. Cytokine. 2015;74(1):62-8. DOI:10.1016/j.cyto.2014.12.024
25. Wu JW, Hu H, Li D, Ma LK. Hypoxia-inducible factor 2-alpha-dependent induction of IL-6 protects the heart from ischemia/reperfusion injury. Aging (Albany NY). 2021;13(3):3443-58. DOI:10.18632/aging.202276
26. Smart N, Mojet MH, Latchman DS, et al. IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes. Cardiovasc Res. 2006;69:164-77.
DOI:10.1016/j.cardiores.2005.08.017
27. Dawn B, Xuan YT, Guo Y, et al. IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. Cardiovasc Res. 2004;64:61-71.
DOI:10.1016/j.cardiores.2004.05.011
28. Hilfiker-Kleiner D, Shukla P, Klein G, et al. Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. Circulation. 2010;122:145‑55. DOI:10.1161/CIRCULATIONAHA.109.933127
29. Danesh J, Kaptoge S, Mann AG, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS medicine. 2008;5:e78. DOI:10.1371/journal.pmed.0050078
30. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood. 1995;86(4):1243-54.
DOI:10.1182/blood.V86.4.1243.bloodjournal8641243
31. Yamamoto K, Rose-John S. Therapeutic Blockade of Interleukin-6 in Chronic Inflammatory Disease. Clin Pharmacol Ther. 2012;91(4):574‑6. DOI:10.1038/cplt.2012.11
32. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006;80(2):227-36. DOI:10.1189/jlb/1105674
33. Askevold ET, Gullestad L, Dahl CP, et al. Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure. Curr Heart Fail Rep. 2014;11(2):146-55. DOI:10.1007/s11897-014-0185-9
34. Jostock T, Mullberg J, Ozbek S, et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem. 2001;268(1):160-7. DOI:10.1046/j.1432-1327.2001.01867.x
35. Чепурнова Д.А., Самойлова Е.В., Анисимов А.А., и др. Компоненты рецепторного комплекса интерлейкина-6 при остром повреждении легких. Бюллетень экспериментальной биологии и медицины. 2018;164(5):609-11 [Chepurnova DA, Samoilova EV, Anisimov AA, et al. Compounds of IL-6 receptor complex during acute lung injury. Bull Exp Biol Med. 2018;164(5):609-11 (in Russian)]. DOI:10.1007/s10517-018-4042-9
36. Korotaeva AA, Samoilova EV, Chepurnova DA, et al. Soluble glycoprotein 130 is inversely related to severity of coronary atherosclerosis. Biomarkers. 2018;23(2):1-18. DOI:10.1080/1354750X.2018.1458151
37. Zhou M, Dai W, Cui Y, et al. Associations between the IL-6-neutralizing sIL-6R-sgp130 buffer system and coronary artery disease in postmenopausal women. Ann Transl Med. 2020;8(6):379-90. DOI:10.21037/atm.2020.02.27
38. Самойлова Е.В., Миндзаев Д.Р., Чепурнова Д.А., и др. Циркулирующий гликопротеин 130 у пациентов с различной степенью выраженности симптомов хронической сердечной недостаточности. Кардиологический вестник. 2019;3:57-61 [Samoilova EV, Mindzaev DR, Chepurnova DA, et al. Circulating glycoprotein 130 in patients with chronic heart failure of varying symptom degrees. Kardiologicheskii vestnik. 2019;3:57-61 (in Russian)].
DOI:10.36396/MS.2019.14.03.009
39. Hirota H, Izumi M, Hamaguchi T, et al. Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure. Heart Vessels. 2004;19(5):237-41. DOI:10.1007/s00380-004-0770-z
40. Askevold ET, Nymo S, Ueland T, et al. Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Circ Heart Fail. 2013;6(1):91-8.
DOI:10.1161/CIRCHEARTFAILURE.112.972653
41. McElvaney OJ, Curley GF, Rose-John S, McElvaney NG. Interleukin-6: obstacles to targeting a complex cytokine in critical illness. Lancet Respir Med. 2021:9(6):643-54. DOI:10.1016/S2213-2600(21)00103-X
42. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011;121(9):3375-83. DOI:10.1172/JCI57158
43. Rabe B, Chalaris A, May U. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood. 2008;111:1021-8. DOI:10.1182/blood-2007-07-102137

________________________________________________

1. Tereshchenko SN, Galyavich AS, Uskach TM, et al. Clinical practice guidelines for Chronic heart failure 2020. Russian Journal of Cardiology. 2020;25(11):311-74 (in Russian).
DOI:10.15829/1560-4071-2020-4083
2. Ponikowski P, Voors AA, Anker DS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Russian Journal of Cardiology. 2017;1(141):7-81 (in Russian). DOI:10.15829/1560-4071-2017-1-7-81
3. Li Z, Zhao H, Wang J. Metabolism and chronic inflammation: the links between chronic heart failure and comorbidities. Front Cardiovasc Med. 2021;8:650278. DOI:10.3389/fcvm.2021.650278
4. Mann DL. Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol. 2003;65:81-101.
DOI:10.1146/annurev.physiol.65.092101.142249
5. Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res. 2015;116:1254-68.
DOI:10.1161/CIRCRESAHA.116.302317
6. Hanna A, Frangogiannis NG. inflammatory cytokines and chemokines as therapeutic targets in heart failure. Cardiovasc Drugs Ther. 2020;34(6):849-63.
DOI:10.1007/s10557-020-07071-0
7. Kalogeropoulos A, Georgiopoulou V, Psaty BM, et al. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol. 2010;55(19):2129-37. DOI:10.1016/j.jacc.2009.12.045
8. van Wijk SS, van Empel V, Davarzani N, et al. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. Eur J Heart Fail. 2015;17:1006-14. DOI:10.1002/ejhf.414
9. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263-71.
DOI:10.1016/j.jacc.2013.02.092
10. Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018;39(1):26-35. DOI:10.1093/eurheartj/ehx564
11. Van Linthout S, Tschope СC. inflammation – cause or consequence of heart failure or both? Curr Heart Fail Rep. 2017;14(4):251-65. DOI:10.1007/s11897-017-0337-9
12. Gullestad L, Ueland T, Fjeld JG, et al. Effect ofthalidomide oncardiac remodelinginchronic heart failure: results of a double-blind, placebo-controlled study. Circulation. 2005;112(22):3408-14.
DOI:10.1161/CIRCULATIONAHA.105.564971
13. Skudicky D, Bergemann A, Sliwa K, et al. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study. Circulation. 2001;103(8):1083-8. DOI:10.1161/01.cir.103.8.1083
14. Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 2001;103(2):220-5. DOI:10.1161/01.cir.103.2.220
15. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107(25):3133-40. DOI:10.1161/01.CIR.0000077913.60364.D2
16. Mann DL, McMurray J, Packer M, et al. Targeted аnticytokine therapy in patients with chronic yeart failure. Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109(13):1594-602. DOI:10.1161/01.CIR.0000124490.27666.B2
17. Torre-Amione G, Anker SD, Bourge RC, et al. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet. 2008;371(9608):228-36. DOI:10.1016/S0140-6736(08)60134-8
18. Ridker PM, Everett BM, Thuren T, et al.; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-31. DOI:10.1056/NEJMoa1707914
19. Van Tassell BW, Trankle CR, Canada JM, et al. IL-1 blockade in patients with heart failure with preserved ejection fraction. Circ Heart Fail. 2018;11(8):e005036.
DOI:10.1161/CIRCHEARTFAILURE.118.005036
20. Abbate A, Trankle CR, Buckley LF, et al. Interleukin-1 Blockade Inhibits the Acute Inflammatory response in patients with st-segment-elevation myocardial infarction. Am J Cardiol. 2020;9(5):e014941. DOI:10.1161/JAHA.119.014941
21. Morton AC, Rothman AM, Greenwood JP, et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J. 2015;36:377-84. DOI:10.1093/eurheartj/ehu272
22. Yan AT, Yan RT, Cushman M, et al. Relationship of interleukin-6 with regional and global left-ventricular function in asymptomatic individuals without clinical cardiovascular disease: insights from the Multi-Ethnic Study of Atherosclerosis. Eur Heart J. 2010;31(7):875‑82. DOI:10.1093/eurheartj/ehp454
23. Harhay MO, Tracy RP, Bagiella E, et al. Relationship of CRP, IL‑6, and fibrinogen with right ventricular structure and function: The MESA-Right Ventricle Study. Int J Cardiol. 2013;168(4):3818-24. DOI:10.1016/j.ijcard.2013.06.028
24. Fontes JA, Rose NR, Cihakova D. The varying faces of IL-6: from cardiac protection to cardiac failure. Cytokine. 2015;74(1):62-8. DOI:10.1016/j.cyto.2014.12.024
25. Wu JW, Hu H, Li D, Ma LK. Hypoxia-inducible factor 2-alpha-dependent induction of IL-6 protects the heart from ischemia/reperfusion injury. Aging (Albany NY). 2021;13(3):3443-58. DOI:10.18632/aging.202276
26. Smart N, Mojet MH, Latchman DS, et al. IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes. Cardiovasc Res. 2006;69:164-77.
DOI:10.1016/j.cardiores.2005.08.017
27. Dawn B, Xuan YT, Guo Y, et al. IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. Cardiovasc Res. 2004;64:61-71.
DOI:10.1016/j.cardiores.2004.05.011
28. Hilfiker-Kleiner D, Shukla P, Klein G, et al. Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. Circulation. 2010;122:145‑55. DOI:10.1161/CIRCULATIONAHA.109.933127
29. Danesh J, Kaptoge S, Mann AG, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS medicine. 2008;5:e78. DOI:10.1371/journal.pmed.0050078
30. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood. 1995;86(4):1243-54.
DOI:10.1182/blood.V86.4.1243.bloodjournal8641243
31. Yamamoto K, Rose-John S. Therapeutic Blockade of Interleukin-6 in Chronic Inflammatory Disease. Clin Pharmacol Ther. 2012;91(4):574‑6. DOI:10.1038/cplt.2012.11
32. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006;80(2):227-36. DOI:10.1189/jlb/1105674
33. Askevold ET, Gullestad L, Dahl CP, et al. Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure. Curr Heart Fail Rep. 2014;11(2):146-55. DOI:10.1007/s11897-014-0185-9
34. Jostock T, Mullberg J, Ozbek S, et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem. 2001;268(1):160-7. DOI:10.1046/j.1432-1327.2001.01867.x
35. Chepurnova DA, Samoilova EV, Anisimov AA, et al. Compounds of IL-6 receptor complex during acute lung injury. Bull Exp Biol Med. 2018;164(5):609-11 (in Russian). DOI:10.1007/s10517-018-4042-9
36. Korotaeva AA, Samoilova EV, Chepurnova DA, et al. Soluble glycoprotein 130 is inversely related to severity of coronary atherosclerosis. Biomarkers. 2018;23(2):1-18. DOI:10.1080/1354750X.2018.1458151
37. Zhou M, Dai W, Cui Y, et al. Associations between the IL-6-neutralizing sIL-6R-sgp130 buffer system and coronary artery disease in postmenopausal women. Ann Transl Med. 2020;8(6):379-90. DOI:10.21037/atm.2020.02.27
38. Samoilova EV, Mindzaev DR, Chepurnova DA, et al. Circulating glycoprotein 130 in patients with chronic heart failure of varying symptom degrees. Kardiologicheskii vestnik. 2019;3:57-61 (in Russian).
DOI:10.36396/MS.2019.14.03.009
39. Hirota H, Izumi M, Hamaguchi T, et al. Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure. Heart Vessels. 2004;19(5):237-41. DOI:10.1007/s00380-004-0770-z
40. Askevold ET, Nymo S, Ueland T, et al. Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Circ Heart Fail. 2013;6(1):91-8.
DOI:10.1161/CIRCHEARTFAILURE.112.972653
41. McElvaney OJ, Curley GF, Rose-John S, McElvaney NG. Interleukin-6: obstacles to targeting a complex cytokine in critical illness. Lancet Respir Med. 2021:9(6):643-54. DOI:10.1016/S2213-2600(21)00103-X
42. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011;121(9):3375-83. DOI:10.1172/JCI57158
43. Rabe B, Chalaris A, May U. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood. 2008;111:1021-8. DOI:10.1182/blood-2007-07-102137

Авторы

А.А. Коротаева1, Е.В. Самойлова*1, Д.Р. Миндзаев1, С.Н. Насонова1, И.В. Жиров1,2, С.Н. Терещенко1,2

1 ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России, Москва, Россия;
2 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия
*erihter@mail.ru

________________________________________________

Alexandra A. Korotaeva1, Elena V. Samoilova*1, Dzambolat R. Mindzaev1, Svetlana N. Nasonova1, Igor V. Zhirov1,2, Sergei N. Tereschenko1,2

1 National Medical Research Center for Cardiology, Moscow, Russia;
2 Russian Medical Academy of Continuing Professional Education, Moscow, Russia
образования» Минздрава России, Москва, Россия
*erihter@mail.ru

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.